PhD defence A. (Amber) Blaauboer

Gemcitabine Resistance in Pancreatic Cancer: Challenging an old foe

Prof. dr. C.H.J. van Eijck


Prof. dr. L.J. Hofland

Tuesday 30 Aug 2022, 10:30 - 12:00
PhD defence
Professor Andries Querido room
Education Center
Erasmus MC
Add to calendar

On Tuesday, 30 August 2022, A. Blaauboer will defend her PhD dissertation, entitled: ‘Gemcitabine Resistance in Pancreatic Cancer: Challenging an old foe’.

Dissertation in short::

Pancreatic cancer is a highly aggressive malignancy with a dismal prognosis. Surgery with adjuvant chemotherapy offers the only curative approach for patients with resectable disease.

For many years, gemcitabine was considered as the first-line adjuvant chemotherapeutic agent. However, during the last decade, more effective chemotherapies, such as FOLFIRINOX, have become of interest. A significant disadvantage of these novel systemic therapies are the severe side-effects. Hence, gemcitabine is still being recommended for patients with poor or declining performance status, as it is much better tolerated with less toxicity.

Suboptimal clinical effects are frequently reported in patients treated with gemcitabine and are primarily due to molecular mechanisms limiting the cellular uptake and activation of gemcitabine and thus its overall efficacy.

In this thesis, we aimed to increase gemcitabine efficacy with addition of two different classes of drugs, i.e., interferon-beta (IFN-β) and epi-drugs. Here, we focused on expression of genes involved in gemcitabine transport and metabolism. 

More information

The public defence will begin exactly at 10.30 hrs. The doors will be closed once the public defence starts, latecomers can access the hall via the fourth floor. Due to the solemn nature of the ceremony, we recommend that you do not take children under the age of 6 to the first part of the ceremony.

A live stream link has been provided to the candidate.



Compare @count study programme

  • @title

    • Duration: @duration
Compare study programmes